EP2755688A4 - HUMANIZED ANTIBODIES DIRECTED AGAINST INKT - Google Patents

HUMANIZED ANTIBODIES DIRECTED AGAINST INKT

Info

Publication number: EP2755688A4
Authority: EP; European Patent Office
Prior art keywords: directed against; humanized antibodies; antibodies directed; inkt; against inkt
Prior art date: 2011-10-27
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP12843689.6A

Other languages

German (de)

French (fr)

Other versions

EP2755688A1 (en

Inventor

Alemseged Truneh

Francis Joseph Carr

Timothy David Jones

James P Gregson

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

NKT Therapeutics Inc

Original Assignee

NKT Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2011-10-27

Filing date

2012-10-26

Publication date

2014-08-06

2012-10-26 Application filed by NKT Therapeutics Inc filed Critical NKT Therapeutics Inc

2014-07-23 Publication of EP2755688A1 publication Critical patent/EP2755688A1/en

2014-08-06 Publication of EP2755688A4 publication Critical patent/EP2755688A4/en

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pulmonology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Biomedical Technology (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Urology & Nephrology (AREA)
Hematology (AREA)
Transplantation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

EP12843689.6A 2011-10-27 2012-10-26 HUMANIZED ANTIBODIES DIRECTED AGAINST INKT Withdrawn EP2755688A4 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201161552337P	2011-10-27	2011-10-27
PCT/US2012/062124 WO2013063395A1 (en)	2011-10-27	2012-10-26	Humanized antibodies to inkt

Publications (2)

Publication Number	Publication Date
EP2755688A1 EP2755688A1 (en)	2014-07-23
EP2755688A4 true EP2755688A4 (en)	2014-08-06

Family

ID=48168549

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP12843689.6A Withdrawn EP2755688A4 (en)	2011-10-27	2012-10-26	HUMANIZED ANTIBODIES DIRECTED AGAINST INKT

Country Status (13)

Country	Link
US (1)	US9932402B2 (en)
EP (1)	EP2755688A4 (en)
JP (1)	JP2015502340A (en)
KR (1)	KR20140093964A (en)
CN (1)	CN103945867B (en)
AU (1)	AU2012328588C1 (en)
BR (1)	BR112014009962A2 (en)
CA (1)	CA2853719A1 (en)
HK (2)	HK1199405A1 (en)
IL (1)	IL232017A0 (en)
RU (1)	RU2014120694A (en)
SG (1)	SG11201401319XA (en)
WO (1)	WO2013063395A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20140271629A1 (en) *	2013-03-14	2014-09-18	Amgen Inc.	Chrdl-1 antigen binding proteins and methods of treatment
US20150165021A1 (en) *	2013-11-05	2015-06-18	Nkt Therapeutics Inc.	Combination therapy
KR102446386B1 (en) *	2014-01-10	2022-09-22	아납티스바이오, 아이엔씨.	Antibodies directed against interleukin-33 (il-33)
EP3104864A1 (en) *	2014-02-14	2016-12-21	INSERM (Institut National de la Santé et de la Recherche Médicale)	Methods and pharmaceutical compositions for the treatment of acute exacerbations of chronic obstructive pulmonary disease
TWI734975B (en) *	2014-06-27	2021-08-01	美商Ｃ２Ｎ醫療診斷有限責任公司	Humanized anti-tau antibodies
EP3190415B1 (en)	2014-07-25	2019-05-01	Riken	Memory invariant nkt cell marker
US20160022777A1 (en) *	2014-07-28	2016-01-28	Nkt Therapeutics Inc.	Combination therapy with il-12
US11933786B2 (en)	2015-03-30	2024-03-19	Stcube, Inc.	Antibodies specific to glycosylated PD-L1 and methods of use thereof
JP7003036B2 (en)	2015-12-02	2022-02-04	エスティーキューブ，インコーポレイテッド	Antibodies specific for glycosylated PD-1 and how to use them
WO2017172517A1 (en)	2016-03-29	2017-10-05	Stcube & Co., Inc.	Methods for selecting antibodies that specifically bind glycosylated immune checkpoint proteins
PE20190209A1 (en)	2016-04-04	2019-02-07	Bioverativ Usa Inc	COMPLEMENT ANTI-FACTOR BB ANTIBODIES AND USE OF THEM
EP3487883B1 (en)	2016-07-20	2023-01-04	Stcube, Inc.	Methods of cancer treatment and therapy using a combination of antibodies that bind glycosylated pd-l1
AU2017327828B2 (en) *	2016-09-16	2023-11-16	Shanghai Henlius Biotech, Inc.	Anti-PD-1 antibodies
CN113508137B (en) *	2019-01-29	2024-12-20	上海交通大学	Chimeric antigen receptor and its application
US11242382B2 (en) *	2020-04-20	2022-02-08	Genzyme Corporation	Humanized anti-complement factor Bb antibodies
CN115666586A (en) *	2020-04-23	2023-01-31	加州大学评议会	Clear senescent cells by activating iNKT cells
AU2022228420A1 (en)	2021-03-01	2023-10-05	Deciduous Therapeutics, Inc.	Compounds for activating invariant natural killer t-cells and methods of use in eliminating inflammatory senescent cells

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001098357A2 (en) *	2000-06-19	2001-12-27	Beth Israel Deaconess Medical Center	Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
US20080254037A1 (en) *	2007-04-12	2008-10-16	University Of Virginia Patent Foundation	Method of treating ischemia reperfusion injury by inhibing nkt cell activity
WO2009026412A1 (en) *	2007-08-21	2009-02-26	Children's Medical Center Corporation	Treatment of airway hyperreactivity

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7119248B1 (en)	1994-04-12	2006-10-10	Miltenyi Biotec Gmbh	Antibodies against epitopes with homology to self antigens, methods of preparation and applications thereof
WO1997016203A1 (en)	1995-11-01	1997-05-09	Genetics Institute, Inc.	Methods for administration of il-12
US6162609A (en)	1997-12-31	2000-12-19	The Brigham And Women's Hospital, Inc.	Diagnostic and therapeutic methods based upon Vα24JαQT cells
WO2003007889A2 (en) *	2001-07-17	2003-01-30	Research Development Foundation	Therapeutic agents comprising pro-apoptotic proteins
ES2365210T3 (en)	2002-06-14	2011-09-26	Government Of The United States Of America, As Represented By The Secretary, Department Of Health	TREATMENT AND COLOR PREVENTION PROCEDURES IN WHICH IL-13 AND NATURAL CYTOLYTIC T-LYMPHOCYTES ARE INVOLVED.
US9809654B2 (en) *	2002-09-27	2017-11-07	Vaccinex, Inc.	Targeted CD1d molecules
KR101377116B1 (en) *	2004-08-27	2014-03-24	알버트 아인슈타인 컬리지 오브 메디신 오브 예쉬바 유니버시티	Ceramide derivatives as modulators of immunity and autoimmunity
WO2006060117A2 (en) *	2004-11-02	2006-06-08	The Board Of Trustees Of The Leland Stanford Junior University	Methods for inhibition of nkt cells
PE20071101A1 (en) *	2005-08-31	2007-12-21	Amgen Inc	POLYPEPTIDES AND ANTIBODIES
WO2008140487A2 (en)	2006-11-14	2008-11-20	Elusys Therapeutics, Inc.	Improved staphylococcal protein a mono- and bispecific antibodies and methods of their use
WO2008100912A1 (en) *	2007-02-12	2008-08-21	The General Hospital Corporation	Methods for attenuating allergen-induced airway hyperreactivity using cd1d dependent antagonists
WO2009015279A2 (en) *	2007-07-24	2009-01-29	National Jewish Medical And Research Center	Agents and methods for inhibition of airway hyperresponsiveness
EP2586797A3 (en) *	2007-11-27	2013-07-24	Medtronic, Inc.	Humanized anti-amyloid beta antibodies
GB0902916D0 (en) *	2009-02-20	2009-04-08	Fusion Antibodies Ltd	Antibody therapy
US8835613B2 (en)	2010-03-12	2014-09-16	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	β-mannosylceramide and stimulation of NKT cell anti-tumor immunity
EP2575824A4 (en)	2010-05-24	2014-02-19	Childrens Medical Center	METHODS FOR THE TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES
EP2785683B1 (en)	2011-11-30	2020-02-05	Ludwig Institute for Cancer Research Ltd.	Inkt cell modulators and methods of using the same
US20150165021A1 (en)	2013-11-05	2015-06-18	Nkt Therapeutics Inc.	Combination therapy
US20160022777A1 (en)	2014-07-28	2016-01-28	Nkt Therapeutics Inc.	Combination therapy with il-12

2012
- 2012-10-26 KR KR1020147014125A patent/KR20140093964A/en not_active Abandoned
- 2012-10-26 BR BR112014009962A patent/BR112014009962A2/en not_active IP Right Cessation
- 2012-10-26 JP JP2014539044A patent/JP2015502340A/en active Pending
- 2012-10-26 WO PCT/US2012/062124 patent/WO2013063395A1/en active Application Filing
- 2012-10-26 SG SG11201401319XA patent/SG11201401319XA/en unknown
- 2012-10-26 US US13/661,386 patent/US9932402B2/en not_active Expired - Fee Related
- 2012-10-26 CN CN201280053174.3A patent/CN103945867B/en not_active Expired - Fee Related
- 2012-10-26 RU RU2014120694/10A patent/RU2014120694A/en not_active Application Discontinuation
- 2012-10-26 AU AU2012328588A patent/AU2012328588C1/en not_active Ceased
- 2012-10-26 CA CA2853719A patent/CA2853719A1/en not_active Abandoned
- 2012-10-26 EP EP12843689.6A patent/EP2755688A4/en not_active Withdrawn
2014
- 2014-04-08 IL IL232017A patent/IL232017A0/en unknown
- 2014-12-29 HK HK14113013.0A patent/HK1199405A1/en unknown
2015
- 2015-01-14 HK HK15100381.0A patent/HK1199837A1/en unknown

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2001098357A2 (en) *	2000-06-19	2001-12-27	Beth Israel Deaconess Medical Center	Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations
US20080254037A1 (en) *	2007-04-12	2008-10-16	University Of Virginia Patent Foundation	Method of treating ischemia reperfusion injury by inhibing nkt cell activity
WO2009026412A1 (en) *	2007-08-21	2009-02-26	Children's Medical Center Corporation	Treatment of airway hyperreactivity

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
"Natural killer T cells and the regulation of asthma", MUCOSAL IMMUNOLOGY; NATURE PUBLISHING GROUP, vol. 2, no. 5, 1 September 2009 (2009-09-01), XP055092762, DOI: 10.1038/mi2009.96 *
FELIX SCHEUPLEIN ET AL: "A Humanized Monoclonal Antibody Specific for Invariant Natural Killer T (iNKT) Cells for In Vivo Depletion", PLOS ONE, vol. 8, no. 9, 1 September 2013 (2013-09-01), pages e76692, XP055120992, ISSN: 1932-6203, DOI: 10.1371/journal.pone.0076692 *
JOSHUA J FIELD ET AL: "Targeting iNKT cells for the treatment of sickle cell disease", CLINICAL IMMUNOLOGY, ACADEMIC PRESS, US, vol. 140, no. 2, 2 March 2011 (2011-03-02), pages 177 - 183, XP028242421, ISSN: 1521-6616, [retrieved on 20110308], DOI: 10.1016/J.CLIM.2011.03.002 *
See also references of WO2013063395A1 *
V. LOMBARDI ET AL: "A CD1d-Dependent Antagonist Inhibits the Activation of Invariant NKT Cells and Prevents Development of Allergen-Induced Airway Hyperreactivity", THE JOURNAL OF IMMUNOLOGY, vol. 184, no. 4, 15 February 2010 (2010-02-15), pages 2107 - 2115, XP055121107, ISSN: 0022-1767, DOI: 10.4049/jimmunol.0901208 *

Also Published As

Publication number	Publication date
EP2755688A1 (en)	2014-07-23
CN103945867A (en)	2014-07-23
SG11201401319XA (en)	2014-06-27
CN103945867B (en)	2018-01-02
WO2013063395A1 (en)	2013-05-02
AU2012328588A1 (en)	2014-04-24
AU2012328588B2 (en)	2015-07-09
BR112014009962A2 (en)	2019-09-24
JP2015502340A (en)	2015-01-22
IL232017A0 (en)	2014-05-28
CA2853719A1 (en)	2013-05-02
US20130136735A1 (en)	2013-05-30
RU2014120694A (en)	2015-12-10
KR20140093964A (en)	2014-07-29
US9932402B2 (en)	2018-04-03
AU2012328588C1 (en)	2015-12-03
HK1199837A1 (en)	2015-07-24
HK1199405A1 (en)	2015-07-03

Publication	Publication Date	Title
HUS2300021I1 (en)	2023-07-28	Anti-IL-36R antibodies
HRP20180640T1 (en)	2018-06-01	Anti-b7-h3 antibody
EP2755688A4 (en)	2014-08-06	HUMANIZED ANTIBODIES DIRECTED AGAINST INKT
IL259826A (en)	2018-07-31	Anti-alphabetatcr antibody
EP2714735A4 (en)	2014-12-31	TGF-BETA-SPECIFIC ANTIBODIES
DK2521736T3 (en)	2019-10-28	Humanized antibodies
DK3842456T3 (en)	2024-10-28	Monoclonal Interleukin-31 Antibody
DK3275892T3 (en)	2020-04-06	PRÆFUSIONS-RSV F ANTIGENS
GB201103955D0 (en)	2011-04-20	Antibodies
GB201112056D0 (en)	2011-08-31	Antibodies
BR112012030311A2 (en)	2017-01-24	antibody
CR20130228A (en)	2013-09-18	ANTI-CCL20 NEUTRALIZING ANTIBODIES
CO6791565A2 (en)	2013-11-14	Anti-notch1 antibodies
CO6801637A2 (en)	2013-11-29	Antibody formulations
HUE050858T2 (en)	2021-01-28	Antibodies against VLA-4
HUE036157T2 (en)	2018-06-28	Humanized IL-25 antibodies
TWI563004B (en)	2016-12-21	Anti-hxcr1 antibody
CO6841994A2 (en)	2014-01-20	Antibodies
LT2742068T (en)	2019-07-10	NEW ANTIBODIES AGAINST PHOSPHORYCHOLINE
EP2714074A4 (en)	2015-04-22	Anti-emr1 antibodies

Legal Events

Date	Code	Title	Description
2014-06-20	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2014-07-23	17P	Request for examination filed	Effective date: 20140416
2014-07-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2014-08-06	A4	Supplementary search report drawn up and despatched	Effective date: 20140709
2014-08-06	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/395 20060101AFI20140703BHEP
2014-08-27	17Q	First examination report despatched	Effective date: 20140725
2015-02-04	DAX	Request for extension of the european patent (deleted)
2015-07-24	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1199837 Country of ref document: HK
2016-12-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: EXAMINATION IS IN PROGRESS
2018-04-18	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 39/00 20060101AFI20180312BHEP Ipc: C07K 16/28 20060101ALI20180312BHEP
2018-04-30	GRAP	Despatch of communication of intention to grant a patent	Free format text: ORIGINAL CODE: EPIDOSNIGR1
2018-04-30	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: GRANT OF PATENT IS INTENDED
2018-05-23	INTG	Intention to grant announced	Effective date: 20180430
2019-02-01	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2019-03-06	18D	Application deemed to be withdrawn	Effective date: 20180911
2021-06-11	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1199837 Country of ref document: HK